{"nctId":"NCT01751867","briefTitle":"An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome","startDateStruct":{"date":"2009-08"},"conditions":["Myelodysplastic Syndrome"],"count":135,"armGroups":[{"label":"3-Day Dose schedule","type":"EXPERIMENTAL","interventionNames":["Drug: Decitabine at 15 mg/m2"]},{"label":"5-Day Dose schedule","type":"EXPERIMENTAL","interventionNames":["Drug: Decitabine at 20 mg/m2"]}],"interventions":[{"name":"Decitabine at 15 mg/m2","otherNames":[]},{"name":"Decitabine at 20 mg/m2","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have diagnosed with Myelodysplastic Syndrome (MDS) denovo (previously not present) or secondary as per the classification of French-American-British (FAB) and International Prognostic Scoring System (IPSS) greater than or eaul to 0.5 as determined by complete blood count (CBC), bone marrow assessment and bone marrow cytogenetics\n* Must have an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2\n* Must have adequate hepatic and renal function as measured by the aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin and serum creatinine, respectively\n* Must have recovered from all toxic effects of prior therapy and not received any chemotherapy for a minimum of 4 weeks (6 weeks if the patient has been treated with a nitrosoureas) prior to the first dose of study drug - Woman must be postmenopausal, or surgically sterile, or abstinent, or, if sexually active, be practicing an effective method of birth control (eg, oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization)\n\nExclusion Criteria:\n\n* Must not have a diagnosis of acute myeloid leukemia (greater than 30% bone marrow blasts) - Must not have received radiotherapy within 14 days before the first dose of study drug - Must not have any other prior cancer, other than superficial bladder cancer, basal cell skin and cervical cancer - Must not have associated autoimmune hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow - Must not have a mental illness or any other condition (eg, uncontrolled cardiac or pulmonary disease, diabetes), that could prevent full cooperation with the study requirements.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria","description":"IWG 2006 response criteria - CR: bone marrow evaluation shows less than or equal to (\\<=) 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin \\>= 11 gram per deciliter (g/dL), neutrophils \\>= 1000/mL, platelets \\>= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by \\>=50%, still greater than 5% in bone marrow.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Hematological Improvement Rate: Number of Participants Who Achieved Complete Remission (CR), Partial Remission (PR) and Hematologic Improvement (HI) - International Working Group (IWG) 2006 Response Criteria","description":"IWG 2006 response criteria - CR: bone marrow evaluation shows \\<= 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin \\>= 11 g/dL, neutrophils \\>= 1000/mL, platelets \\>= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by \\>= 50%, still greater than 5% in bone marrow; HI: hemoglobin increase of \\>= 1.5 g/dL, platelet increase of \\>= 30,000/mL (starting with \\> 20,000/mL), neutrophils increase of \\>= 100% and \\> 500/Î¼L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Cytogenetic Response Rate: Percentage of Participants Who Achieved Cytogenetic Response (Complete+Partial) by Status of Clinical Overall Response - International Working Group (IWG) 2006 Response Criteria","description":"As per IWG 2006 response criteria - Complete cytogenetic response: disappearance of the chromosomal abnormality without appearance of new ones; Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality. Status of Clinical response - complete remission (CR); marrow CR (mCR); partial remission (PR).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"84.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Transfusion Independence: Number of Participants Who Were Transfusion Independent","description":"A participant was considered to be transfusion independent, if the participant had no transfusions of Red Blood Cells (RBCs) or platelets for 8 consecutive weeks or more.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percentage of Duration of Hospitalization (Relative to Days on Study Treatment)","description":"Duration of hospitalization was calculated as, total number of days a participant stayed in hospital during study treatment divided by the study treatment duration","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"34.20"},{"groupId":"OG001","value":"59.2","spread":"34.17"}]}]}]},{"type":"SECONDARY","title":"Overall Survival Rate: Percentage of Participants Who Survived During 6 Months and 12 Months of Treatment.","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","spread":null},{"groupId":"OG001","value":"65.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to End of Treatment in Scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ C-30) Physical Functioning Scale","description":"EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from \"1 = not at all\" to \"4 = very much\". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which will be rated on a 7-point scale ranging from \"1 = very poor\" to \"7 = excellent\". Lower scores indicate worsening. Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"29.48"},{"groupId":"OG001","value":"-9.1","spread":"26.34"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":34},"commonTop":["White blood cell count decreased","Platelet count decreased","Pyrexia","Neutrophil count decreased","Haemoglobin decreased"]}}}